Loss to follow-up (LTFU) in HIV-positive cohorts is an important surrogate for interrupted clinical care, which can potentially influence the assessment of HIV disease status and outcomes. After preliminary evaluation of LTFU rates and patient characteristics, we evaluated the risk of mortality by LTFU status in a high-resource setting.
Methods
Rates of LTFU were measured in the Australian HIV Observational Database for a range of patient characteristics. Multivariate repeated measures regression methods were used to identify determinants of LTFU. Mortality by LTFU status was ascertained using linkage to the National Death Index. Survival following combination antiretroviral therapy initiation was investigated using the Kaplan–Meier (KM) method and Cox proportional hazards models.
Results
Of 3,413 patients included in this analysis, 1,632 (47.8%) had at least one episode of LTFU after enrolment. Multivariate predictors of LTFU included viral load (VL)>10,000 copies/ml (rate ratio [RR] 1.63; 95% CI 1.45, 1.84; ref ≤400), time under follow-up (per year; RR 1.03; 95% CI 1.02, 1.04) and prior LTFU (per episode; RR 1.15; 95% CI 1.06, 1.24). KM curves for survival were similar by LTFU status (P=0.484). LTFU was not associated with mortality in Cox proportional hazards models (univariate hazard ratio [HR] 0.93; 95% CI 0.69, 1.26) and multivariate HR 1.04 (95% CI 0.77, 1.43).
Conclusions
Increased risk of LTFU was identified amongst patients with potentially higher infectiousness. We did not find significant mortality risk associated with LTFU. This is consistent with timely re-engagement with treatment, possibly via high levels of unreported linkage to other health-care providers.
References
1.
BrinkhofM.W., Pujades-RodriguezM., EggerM.Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis.PLoS ONE2009; 4: e5790.
2.
DalalR.P., MacphailC., MqhayiM.Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa.J Acquir Immune Defic Syndr2008; 47: 101–107.
3.
BrennanA.T., MaskewM., SanneI., FoxM.P.The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa.J Int AIDS Soc2010; 13: 49.
4.
EggerM., SpycherB.D., SidleJ.Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa.PLoS Med2011; 8: e1000390.
5.
EdwardsJ.K., ColeS.R., WestreichD.Loss to clinic and five-year mortality among HIV-infected antiretroviral therapy initiators.PLoS ONE2014; 9: e102305.
6.
HorbergM.A., HurleyL.B., SilverbergM.J., KleinD.B., QuesenberryC.P., MugaveroM.J.Missed office visits and risk of mortality among HIV-infected subjects in a large healthcare system in the United States.AIDS Patient Care STDS2013; 27: 442–449.
7.
LanoyE., LewdenC., LievreL.How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalite 2000 survey and death certificates.HIV Med2009; 10: 236–245.
8.
HillT., BansiL., SabinC.Data linkage reduces loss to follow-up in an observational HIV cohort study.J Clin Epidemiol2010; 63: 1101–1109.
9.
MocroftA., KirkO., AldinsP.Loss to follow-up in an international, multicentre observational study.HIV Med2008; 9: 261–269.
10.
PorterK., JohnsonA.M., PhillipsA.N., DarbyshireJ.H.The practical significance of potential biases in estimates of the AIDS incubation period distribution in the UK register of HIV seroconverters.AIDS1999; 13: 1943–1951.
11.
SimardE.P., PfeifferR.M., EngelsE.A.Mortality due to cancer among people with AIDS: a novel approach using registry-linkage data and population attributable risk methods.AIDS2012; 26: 1311–1318.
12.
FonsecaM.G., CoeliC.M., de Fatima de Araujo LucenaF., VelosoV.G., CarvalhoM.S.Accuracy of a probabilistic record linkage strategy applied to identify deaths among cases reported to the Brazilian AIDS surveillance database.Cad Saude Publica2010; 26: 1431–1438.
13.
Centers for Disease Control and Prevention.Electronic record linkage to identify deaths among persons with AIDS-District of Columbia, 2000–2005.MMWR Morb Mortal Wkly Rep2008; 57: 631–634.
HardingR., KrakauerE.L., SitholeZ., De LimaL., SelmanL.The ‘lost’ HIV population: time to refocus our clinical and research efforts.AIDS2009; 23: 145–146.
16.
Friis-MøllerN., SabinC.A., WeberR.Combination antiretroviral therapy and the risk of myocardial infarction.N Engl J Med2003; 349: 1993–2003.
17.
CullenB.L., CodereG., WallaceL.A., BaguleyS., ClutterbuckD.J.British Association for Sexual Health and HIV Scottish investigation 2010–2011: reasons for non-attendance in individuals lost to follow-up for HIV care for more than 12 months in Scotland.Int J STD AIDS2013; 24: 481–484.
18.
LebouchéB., YazdanpanahY., GerardY.Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998.HIV Med2006; 7: 140–145.
19.
FalsterK., GelgorL., ShaikA.Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment.Sex Health2008; 5: 141–154.
KeiserO., SpycherB., RauchA.Outcomes of antiretroviral therapy in the Swiss HIV Cohort Study: latent class analysis.AIDS Behav2012; 16: 245–255.
25.
AndrewsJ.R., WoodR., BekkerL.G., MiddelkoopK., WalenskyR P.Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care.J Infect Dis2012; 206: 543–551.
26.
RachlisB., BrouwerK.C., MillsE.J., HayesM., KerrT., HoggR.S.Migration and transmission of blood-borne infections among injection drug users: understanding the epidemiologic bridge.Drug Alcohol Depend2007; 90: 107–119.
27.
SouthS.J., CrowderK.D.Residential mobility between cities and suburbs: race, suburbanization, and back-to-the-city moves.Demography1997; 34: 525–538.
28.
WoodE., YipB., GataricN.Determinants of geographic mobility among participants in a population-based HIV/ AIDS drug treatment program.Health Place2000; 6: 33–40.
29.
MaddenH.C., Phillips-HowardP.A., HargreavesS.C.Access to HIV community services by vulnerable populations: evidence from an enhanced HIV/AIDS surveillance system.AIDS Care2011; 23: 542–549.
30.
GermanD., DaveyM.A., LatkinC.A.Residential transience and HIV risk behaviors among injection drug users.AIDS Behav2007; 11 Suppl: 21–30.
31.
StrathdeeS.A., HallettT.B., BobrovaN.HIV and risk environment for injecting drug users: the past, present, and future.Lancet2010; 376: 268–284.
Australian Government Department of Health.Browse by Section 100 Item List: Highly Specialised Drugs program; 2014. (Accessed 12 May 2014.) Available from http://pbs.gov.au/browse/section100-hb?initial=a.
